| INTRODUCTION
Esophageal carcinoma is the eighth most common cancer and the sixth most common cause of cancer deaths worldwide. There are an estimated 17 290 new cases and 15 850 deaths annually in America, and distal esophageal cancer cases are increasing rapidly in developed countries. 1, 2 In recent years, trimodality therapy (neoadjuvant chemoradiation followed by esophagectomy) has improved clinical outcomes in patients with locally advanced esophageal cancers compared to surgery alone. 3, 4 Concurrent chemotherapy, usually with weekly carboplatin and paclitaxel, combined with radiation doses of 41.4-50.4 Gy are considered standard treatments in the modern era. 5 The long-term results of Radiation Therapy Oncology Group (RTOG) clinical trial 85-01 confirmed that chemoradiation increased overall survival for patients with esophageal carcinoma compared with radiotherapy (RT) alone. 5 Due to proximity to surrounding organs at risk (OAR) such as heart, spinal cord, lungs, kidney, liver, and the remaining stomach, the RT planning for distal esophagus carcinoma poses special challenges. 6, 7 Sufficient radiation doses must be applied to the tumor and lymph node areas, while protecting nearby critical normal structures.
Volumetric-modulated arc therapy (VMAT) is an advanced form of intensity-modulated radiation therapy (IMRT) that can deliver a highly conformal dose distribution using single or multiple arcs. 8 Compared with static-field IMRT, VMAT achieves similar OAR sparing and planning target volume (PTV) coverage with significantly shorter treatment time. 9, 10 Proton beam therapy delivers highly conformal target coverage, while sparing adjacent OARs due to its unique Bragg peak dose deposition characteristics. Proton beam therapy 11 has several forms of delivery including passive scattering (PSPT), uniform scanning, and intensity-modulated proton therapy (IMPT). Unlike PSPT, IMPT uses magnetic steering of a narrow proton beam, termed a beamlet, to deliver a modulated dose to a spot of a specified size, which offers improved high-dose conformality compared with PSPT and better OAR sparing in the mid-to lowdose range compared to IMRT. 12, 13 Therefore, it is hypothesized that IMPT can improve the therapeutic ratio which will result in fewer adverse effects, while achieving the same tumor control as IMRT or better. 14 However, IMPT is highly sensitive to setup and range uncertainties, as well as vulnerable to respiratory motion present in the distal esophageal regions. 15, 16 The uncertainties originate from daily patient alignment, conversion of Hounsfield units to stopping power, artifacts in computed tomography, and anatomical changes in patients etc. 17 The interaction between dynamic beamlet delivery and respiratory motion, also called interplay effect, may degrade the quality of planned dose distributions, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] compromising the safety and efficacy of the proposed treatment. In addition, large spot sizes, common in older IMPT machines, tend to lead to larger penumbras, which results in undesired dose to adjacent OARs. The majority of new proton facilities offer smaller spot sizes, which can produce smaller penumbras and better OAR sparing. However, smaller spotsize plans can exacerbate the negative consequences of patient setup uncertainty and make interplay effects more prominent. 25, 31 As a result, we first need to quantify and then mitigate the impact of uncertainties and interplay effects for small-spot IMPT for the treatment of distal esophageal cancers.
Previous studies have focused on the comparison of plan quality alone among plans generated using either PSPT, large-spot IMPT (spot size σ as large as 6-15 mm depending on proton energies), and/or IMRT [32] [33] [34] [35] [36] [37] with no mention of plan uncertainties or motion effect analyses. Recently, Shiraishi et al. reported that in a large cohort of esophageal cancer patients, PSPT and large-spot IMPT significantly reduced radiation exposures to the whole heart and cardiac substructures compared with IMRT. 32 Welsh et al. found that large-spot IMPT for distal esophageal carcinoma also lowered the doses to bilateral lungs and liver compared to IMRT. 37 More recently, a large, retrospective multi-institutional study also demonstrated that proton beam therapy appeared to be more clinically advantageous compared with 3-dimensionl conformal RT and IMRT in lowering the incidence of pulmonary and cardiac complications as well as the mean length of in-hospital stay. 38 To the best of our knowledge, no dosimetric study has been reported comparing plan quality and plan robustness for small-spot IMPT and VMAT in the treatment of distal esophageal cancer. The aim of this study is to evaluate the feasibility of small spot IMPT for such treatments. We compared plan quality and robustness for VMAT and small-spot IMPT. The interplay effects of small-spot IMPT were also quantified.
| MATERIALS AND METHODS

2.A | Patient selection
Nineteen consecutive patients with distal esophageal carcinoma treated with IMPT and 16 patients treated with VMAT between May 2014 and September 2017 at our institution were retrospectively reviewed. 
2.B | Patient simulation and contouring
For both IMPT and VMAT treatments, the processes for patient simulation and contouring were similar. Four-dimensional computed tomography (4D-CT) was used to simulate all patients in the supine position. At our clinic, we defined the respiratory motion amplitude by the largest displacement of tumor geometric center in the ante- first, we identified the appropriate gross target volume (GTV) on the average CT or one of the respiratory phase CT scans, and the coregistered PET and CT scan. Then, a 3-4 cm expansion was added along the mucosal surface longitudinally, in addition to a 1-1.2 cm radial expansion for the CTVs which were anatomically constrained.
The lower CTV volume typically included a small expansion of elective nodal volumes in the para-esophageal region. The treating radiation oncologist also adjusted the expansion of margins based on the pathology and location of the tumor; the potential microscopic tumor extent and anatomic boundaries of heart, lungs, liver, kidneys, and bowel were also taken into consideration in the final target delineation.
2.C | Treatment planning
In VMAT treatment planning, all treatment plans were generated on the averaged CT. We used planning target volumes (PTV), formed by a 5-mm uniform expansion of CTVs, for plan optimization and evaluation in VMAT. Most commonly, 2 to 3 arcs were used. Photon optimizer (PO) model in the Eclipse TM TPS was used for VMAT optimization, and analytical anisotropic algorithm (AAA) model was used for dose calculation. The dose calculation grid size was 3 mm.
The dosimetrists created treatment plans, which satisfied institutional dose constraints ( Usually, 2 to 3 proton beams were used. Single field optimization (SFO) was always the first option, however, multiple-field optimiza- . In addition, a second independent dose calculation was performed using an in-house developed Monte Carlo software. 46 We carefully commissioned our TPS by fudging the proton optics parameters, 47 so the dose distributions calculated by our TPS matched well with those generated by the Monte Carlo simulations. 47, 48 Based on 3 yr clinical experience at our institution, the deviation of CTV D 95%
and D mean between Monte Carlo simulation and TPS computation has been less than 3% and 2% for most of patients respectively.
2.D | Treatment delivery
The Clinac machines (Varian medical system, Palo Alto, CA) were used to deliver the VMAT plans. The related parameters including field information, energy, and estimated delivery duration are shown in Table S1 . Typically, daily on-board imaging or cone-beam CT was used as the image-guided RT methods.
For IMPT, the Hitachi ProBeat-V spot-scanning proton beam machines (Hitachi, Tokyo, Japan) were used. The active scanning proton beam machine was commissioned to have an energy-dependent spot size (σ) of 2 to 6 mm, with a fixed spot spacing of 5 mm.
Our proton beam scanning machine had discrete proton energies ranging from 71.3 to 228.8 MeV. These discrete energies were carefully selected to minimize the ripples in the dose distribution along the beam direction and minimum MU effects. The energy layer switch time for all 97 energies ranged from 1.9 to 2.0 s, with an average of 1.91 s. The average spill length was 7.9 s. The average magnet preparation and verification time was 1.93 ms. 49 The related field and energy choices, estimated delivery duration, and repainting numbers are shown in the Table S2 . We used orthogonal pair kV images to align to bony anatomy during the IMPT treatment.
For both IMPT and VMAT, the set up images were reviewed offline and approved by the treating radiation oncologist to make sure that the patient setup errors were within clinical tolerance. 
2.E | Plan quality evaluation
2.F | Robustness quantification
Patient set up uncertainty is considered to be random and can be modelled as a Gaussian distribution. Range uncertainty is considered to be systematic, but range uncertainty of a large patient population can also be considered to be a Gaussian distribution. 50 The value of 3 mm setup uncertainty and 3% range uncertainty (equal to twice the standard deviation of the setup and range uncertainty distribution) is well-regarded in the proton therapy community. This is applicable for the treatment of distal esophageal carcinoma with plan robustness analysis and also in the use of image-guided radiation therapy.
For IMPT plans, 13 scenarios were taken into account, including For VMAT plans, seven scenarios were considered, including one nominal scenario and six perturbed scenarios. The six perturbed scenarios were created by rigidly shifting the isocenter in the same canonical directions by a distance of 3 mm, but with no range uncertainty considerations. A DVH curve was generated for each uncertainty scenario and consequently a DVH band was formed corresponding to multiple uncertainty scenarios (Fig. 1) . In order to evaluate the robustness of VMAT and IMPT treatment plans, the width of the DVH band was used as a surrogate for robustness indications. The width of the DVH band was the difference between the maximum and minimum of certain DVH indices (Fig. 1) . The CTV-related DVH band width was normalized by the corresponding prescription dose. A smaller DVH band width meant better plan robustness. The DVH data for uncertainty analysis was exported from Eclipse, and the DVH band width was calculated using in-house developed software.
All treatment plans were designed to have CTV high and CTV low D 95% reaching at least 95% of the prescription doses in the worstcase scenarios for all CT phases. Alto, California). Every spot of each field per fraction was assigned to the corresponding respiratory phases according to their temporal relationship with the spot delivery sequence and patient-specific respiratory motion. The spot doses were summed to a reference phase using in-house developed deformable image registration software. 45, 51 The starting phase of each field for each fraction was randomized to minimize the influence of starting phases. The interplay effects were evaluated using the fraction number in the prescription of IMPT treatment (Table S2 ).
2.G | Interplay effect evaluation
The proton absolute dose calibration process follows IAEA TRS-398 protocol. The absolute dose of 1MU for a specific selected beam is 1 cGy. The beam used for calibration is: range 20 cm, spread out Bragg peak (SOBP) 10 cm, and field size 10 cm × 10 cm. It is composed of 27 energy layers (120-173.6 MeV), 289 spots in each layer with 6 mm spot spacing, a total of 200 MU. In IMPT treatment planning, we also used the iso-layer repainting to mitigate interplay effects. 45, 51, 52 For respiratory motion less than or equal to 5 mm, the minimum and maximum MU limits in the proton machine were 0.003 and 0.04 MU, respectively. A smaller maximum MU limit of 0.01 MU was used for cases with respiratory motion greater than 5 mm. The purpose of a smaller maximum MU limit was to make the delivery system perform a larger number of iso-layer repainting, which in turn mitigated the impact of interplay effects. 52, 53 During the delivery process, if the intensity of one spot was larger than the maximum MU limit, the spot was split into multiple spots, and the split spots were appended in the spot list of the same energy layer and delivered individually. For the spots with MU less than the minimum MU limit: if the intensity of one spot was larger than half of Table 3 ].
Some outliers were observed. For example, heart D mean , V 20Gy
[RBE] , and V 30Gy [RBE] in IMPT [Figs. 3(e)-3(f) ]. These outliers were found to come from the same patient. The heart was in close proximity to the CTV high [ Fig. S1(a) ], which resulted in higher dose to the heart [ Fig. S1(b) ]. Similarly, close proximity of the heart to a tumor resulted in the outliers in heart V 30Gy [RBE] and V 40Gy [RBE] [ Fig. 3(f) ] in VMAT. To avoid vital organs including cord and lungs for this patient, we had to limit target dose coverage and homogeneity to some degree in VMAT, resulting in additional outliers in D 5% -D 95% [ Fig. 3(b) ].
3.B | Plan robustness
Considering the plan robustness, the DVH index range of CTVs and
OARs for both treatment groups were compared ( (Fig. 4) .
3.C | Interplay effect
Interplay effects were considered for all of the IMPT plans [see 
| DISCUSSION
The purpose of this comparative planning study was to evaluate the process and feasibility of small-spot machine IMPT in the treatment for distal esophagus carcinoma as well as provide a dosimetric comparison to VMAT in regard to plan quality and robustness.
Small spot-size IMPT is an attractive modality for the treatment of esophageal cancer. Our study compared IMPT with spot sizes of 2-6 mm (σ) with VMAT. We found that small-spot IMPT achieved similar plan quality as VMAT in terms of target dose coverage, homogeneity, and sparing of most OARs. More importantly, it significantly lowered heart, liver, and bilateral lung doses as compared to VMAT. As a result, IMPT will likely reduce the incidence and also severity of RT-induced cardiac and pulmonary toxicities in the longterm and perioperatively. However, the equipoise of such considerations and clinically meaningful significance over conventional treatments such as IMRT or VMAT remain undefined for distal esophageal cancer therapies.
Although small-spot IMPT is potentially capable of producing better plans due to sharper penumbra, the uncertainties due to proton range and patient setup can greatly compromise plan qualities. 56, 57 Therefore, it is important to take into account the uncertainties in treatment planning when using a small-spot IMPT machine to treat patients with esophageal carcinoma. Our study demonstrates that small-spot IMPT treatment plans achieved clinically defined planning requirements in terms of plan robustness and met the clinical standards for RT. Small-spot IMPT should be considered for the routine treatment in patients with distal esophageal carcinoma. However, robustness relative to internal organ motion remains a major challenge in small-spot IMPT treatments for esophageal cance. 30, 33, 45, 53 Compared with IMPT, VMAT has been shown to be more robust with respect to organ motions or anatomic changes. 58 Therefore, it is vital to consider and optimally mitigate the impact of respiratory motions when IMPT is clinically implemented. At our institution, we carefully consider respiratory motion
The comparison of plan quality using dose-volumehistogram (DVH) indices. and V 20Gy [RBE] , and heart D mean for distal esophageal cancer patients. 37 Compared with large-spot IMPT, small-spot IMPT is considered to have two benefits: (a) sharper penumbra, which results from smaller spot sizes, can improve the sparing of organs-at-risk and lead to lower radiation toxicities 52, 59 ; (b) a larger number of spots, which are needed to cover the same tumors compared to large-spot IMPT, provides the TPS more freedom to compensate for the impact of uncertainties and interplay effects. 53 Most of the IMPT plans included in this study were generated using a SFO approach. The few remaining plans were generated using MFO with robust planning from our TPS. [39] [40] [41] [42] [43] After the plan was optimized, we recalculated the dose distributions in the averaged 4D CT, maximum exhale phase CT, and maximum inhale phase CT without density override to evaluate the impact of respiratory motion. The original plan generated on the averaged CT was adjusted until all dose distributions calculated on the averaged CT, maximum exhale phase CT, and maximum inhale phase CT without density override met the institutional dose constraints. All patients were observed to have both CTV high and CTV low D 95% at least 95% of the prescription dose with interplay effects taken into account. As a result, even though some of the patients included in this study have considerable amount of target motion as influenced by respiration (the median value of the amplitude of respiratory motions was 8 mm, with a range of 4 to 13 mm), all of our plans using small-spot IMPT still met the clinical requirement in terms of robustness and interplay effect considerations after these treatment planning measures were taken.
For distal esophageal carcinoma, we commonly used posterior oblique beams in our IMPT treatment: left-right oblique beams or superior-inferior oblique beams. Left-right oblique beams spare the spinal cord, but may be sensitive to respiratory motion (Fig. S2 ). arrangements worked very well for most patients. However, in some scenarios, there were variants of beam arrangements for specific patients: if the patient was pretreated by radiation therapy and the dose in certain organs needed to be limited, three or four beams were used to spare certain organs (Table S2) ; if the patient had significant respiratory motion and two beams could not achieve the plan robustness of clinical requirements, then three or four beams were used to improve the plan robustness (Table S2) .
This study has a number of limitations. First, the number of the patients included in this study was not sufficiently large nor were they matched. The results could be affected by interpatient variability and different planning skills. However, these represented consecutive samples of actual IMPT vs VMAT plans that were delivered in the clinic over a similar period of time. To address the aforementioned issues, a study with a larger patient population with both VMAT and IMPT plans generated for each patient is currently under way to further generalize our conclusions. Second, only a limited number of uncertainty scenarios were considered in this study, which might underestimate the impact of uncertainties in selected IMPT plans.
In the future, other tumor locations (cervical, proximal, and midesophageal) should be considered in further studies. Furthermore, more patient data with short/long-term clinical outcomes, perioperative complications, gradation-related toxicities, and patient-reported outcome should be reported to evaluate the potential clinical benefits of small-spot IMPT over VMAT plans. 
| CONCLUSION
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